Elephas Biosciences Corporation is partnering with the University of Louisville on a new research opportunity that will evaluate the impact of a combination therapy of surgical intervention and immunotherapy in colorectal, liver and pancreatic cancers, the company announced recently.

According to a release, the University of Louisville will be analyzing live tumor specimens on the Elephas Live Platform.

“We are honored to partner with Dr. Martin and the team at the University of Louisville to continue exploring the ways we believe our platform can help to inform better treatment options,” Elephas Founder and CEO Maneesh Arora said in a statement. “Progress in oncology depends on strong collaborations that bring together clinical expertise and advanced technology. These studies can bring meaningful improvements in patient cancer care.”

Financial details of the agreement were not disclosed.